𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer

✍ Scribed by Abbas H. Panju; Henriette Breunis; Angela M. Cheung; Marc Leach; Neil Fleshner; Padraig Warde; Sarah Duff-Canning; Murray Krahn; Gary Naglie; Ian Tannock; George Tomlinson; Shabbir M.H. Alibhai

Book ID
109055459
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
130 KB
Volume
103
Category
Article
ISSN
1464-4096

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Denosumab and changes in bone turnover m
Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer
✍ Matthew R Smith; Fred Saad; Blair Egerdie; Paul Sieber; Teuvo LJ Tammela; Benjam πŸ“‚ Article πŸ“… 2011 πŸ› American Society for Bone and Mineral Research 🌐 English βš– 127 KB

## Abstract Androgen deprivation therapy (ADT) for prostate cancer increases fracture risk, decreases bone mineral density, and increases bone turnover markers (BTMs) including serum type 1 C‐telopeptide (sCTX), tartrate‐resistant alkaline phosphatase 5b (TRAP‐5b), and procollagen‐1 N‐terminal telo